Hyderabad-based integrated research services provider GVK Biosciences (GVK Bio) and Excel PharmaStudies (Excel), a Chinese clinical research organisation, have entered into a strategic alliance to conduct clinical trials in Asia.
The alliance provides clinical trial sponsors access to the scientific skills, talent pool, flexible resourcing, and cost-effectiveness of both India and China, GVK Bio stated in a press release.
Under the terms of the arrangement, GVK Bio and Excel will help sponsors conduct and manage Phase II-IV clinical trials, statistical analysis and medical writing. Any India trial for Excel will be carried out by the GVK Bio clinical research team and will be managed by a core project management team of Excel. Similarly, a GVK Bio China trial will be carried out by the Excel team and managed by GVK Bio’s project management team.
“This is a first of a kind alliance between an Indian CRO and a Chinese CRO. The GVK Bio-Excel alliance integrates trial management across India and China and provides sponsors with a single point of contact,” said Manni Kantipudi, president of GVK Bio.
“It is an important step for Excel, and our clients, to be able to provide full services in both important countries,” William Xiong, chief executive officer of Excel, stated.
The decision to form such an alliance comes close on heels of GVK Bio's increased focus on clinical development. The company had recently strengthened its team by hiring Shoibal Mukherjee, who was earlier with Pfizer, as its clinical development head.
GVK Bio has also added new services in pharmacovigilance and medical writing operating from its clinical research facility in Gurgaon.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
